Endocrinology

Headache Relief Shampoo Voted #1 Best New Product in 2019

headache relief shampoo bottles

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019Comments OffHeadache Drug Trial | Headache Relief | Headache Shampoo | Headache Study | Headache Therapy
The Dietary Guidelines 3 Diet Patterns Study (DG3D): Phase 2

The U.S. Dietary Guidelines (USDG) form the basis of federal nutrition programs and policy and provide valuable guidance to health initiatives and industries. The updated 2015 USDG moved away from a focus on individual nutrients to a greater focus on dietary patterns. The USDG state that healthy eating goals can be met through a variety of dietary patterns, but present healthy diet in three main ways: 1) Healthy U.S.-Style Eating Pattern, 2) Healthy Mediterranean-Style Eating Pattern, and 3) Healthy Vegetarian Eating Pattern. Currently, US adults are falling short of the nutrition recommendations (fruit/vegetable intake, greens/beans, whole grains, etc.) set forth by the USDG and measured by the Healthy Eating Index (HEI). While the USDG are the basis of nutrition guidelines, the research informing these dietary pattern recommendations has largely been drawn from observational studies among mostly white populations. In addition, there has been very limited cultural-tailoring of these dietary patterns that would ensure that these diets are acceptable to diverse populations, in particular, African Americans (AAs) living in the south, who experience a disproportionate burden of chronic disease, especially type 2 diabetes (T2DM). Currently, US adults are not meeting nutrition recommendations (fruit/vegetable, whole grains, etc.) set forth by the USDG and measured by the Healthy Eating Index (HEI).
For this study, AA adult participants with overweight/obesity and ≥three T2DM risk factors will be recruited to participate in the following aim:
Based on the findings of our formative work, conduct a one-year intervention using revised culturally tailored materials to examine differences in HEI and T2DM risk factors among participants (n=198) randomized to one of the 3 dietary patterns. This will result in community-based strategies around presenting dietary guidelines in a way to effectively meet nutrition recommendations leading to significant impacts on health among AA adults.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Intrapartum Glycemic Control in GDMA2

Gestational diabetes mellitus (GDM) remains a common pregnancy complication, affecting 6-15% of pregnancies worldwide. The incidence of GDM is expected to continue its global upward trend in light of the growing obesity epidemic and delayed childbearing. GDM is associated with adverse short- and long-term maternal and offspring outcomes. Neonatal hypoglycemia, as a result of fetal hyperinsulinemia, occurs in up to 35% of pregnancies complicated by GDM with potential long-term neurodevelopmental sequelae. In that regard, significant emphasis has been placed on the prevention of neonatal hypoglycemia through optimal maternal glycemic control. Available data are conflicting as to the contribution of intrapartum glycemia to neonatal glycemia.
Moreover, national guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to a lack of high-quality data on the topic. As far as we are aware, only one single center randomized controlled trial has been published on the topic. That study’s findings suggest that an approach to a more liberalized intrapartum glycemic management was not associated with a higher rate of neonatal hypoglycemia compared to a tight glycemic control regimen. We propose to replicate these findings in a different population at our institution. If this more relaxed approach to intrapartum glycemic management is confirmed to be safe to women and their babies, its clinical application has the potential to decrease the inconvenience of frequent finger pricks for our patients during labor and allow more efficient allocation of resources for the nursing staff on an already labor-intensive unit.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk

Active Comparator: Type 1 Diabetics
All participants will complete 4 visits over 6-8 weeks. Visit 1 is a screening visit which includes a physical exam, a bone mineral density scan, a blood draw and an EKG. Visit 2 consists of dispensing the Tetracycline antibiotic required for the bone biopsy. Visit 3 is the bone biopsy and includes a blood draw. Visit 4 is to remove the stitches.
Procedure: Transilial bone biopsy
The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located ~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
A Study of LY3209590 Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Cahaba Research

Birmingham, Alabama, United States, 35242

Contact    205-408-4134      

Principal Investigator: Jordan Vaughn         

Syed Research Consultants Llc

Sheffield, Alabama, United States, 35660

Contact    256-383-4473      

Principal Investigator: AARON W KARR         

AMCR Institute

Escondido, California, United States, 92025

Contact    760-466-1520      

Principal Investigator: Timothy S. Bailey         

Velocity Clinical Research, Gardena

Gardena, California, United States, 90247

Contact    213-413-2500      

Principal Investigator: Mark T. Leibowitz         

Velocity Clinical Research, Huntington Park

Huntington Park, California, United States, 90255

Contact    323-588-1990      

Principal Investigator: Stanley H. Hsia         

Velocity Clinical Research, Westlake

Los Angeles, California, United States, 90057

Contact    2134132500      

Principal Investigator: Juan Pablo Frias         

Diabetes Associates Medical Group

Orange, California, United States, 92868

Contact    714-639-1815      

Principal Investigator: IVY-JOAN MADU         

Encompass Clinical Research

Spring Valley, California, United States, 91978

Contact    619-660-9068      

Principal Investigator: Hanid Audish         

Millennium Clinical Trials

Thousand Oaks, California, United States, 91360

Contact    805-496-3322      

Principal Investigator: Edward B. Portnoy         

University Clinical Investigators, Inc.

Tustin, California, United States, 92780

Contact    714-734-7944      

Principal Investigator: John Kim         

Diablo Clinical Research, Inc.

Walnut Creek, California, United States, 94598

Contact    925-930-7267      

Principal Investigator: Mark P. Christiansen         

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Contact    303-724-4651      

Principal Investigator: Neda Rasouli         

Chase Medical Research, LLC

Waterbury, Connecticut, United States, 06708

Contact    203-419-4420      

Principal Investigator: Joseph Soufer         

Clinical Research of West Florida, Inc. (Clearwater)

Clearwater, Florida, United States, 33765

Contact    7274660078      

Principal Investigator: Leonard Jay Dunn         

Suncoast Research Group

Miami, Florida, United States, 33135

Contact    3056316704      

Principal Investigator: Mark Eliot Kutner         

Clinical Research of West Florida

Tampa, Florida, United States, 33606

Contact    813-870-1292      

Principal Investigator: Lon D. Lynn, DO         

Center for Advanced Research & Education

Gainesville, Georgia, United States, 30501

Contact    7705345154      

Principal Investigator: Angela Dawn Ritter         

Pacific Diabetes & Endocrine Center

Honolulu, Hawaii, United States, 96813

Contact    808-526-0303      

Principal Investigator: ALAN PARSA         

Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative

Springfield, Illinois, United States, 62711

Contact    217-546-2064      

Principal Investigator: Diana Widicus         

American Health Network of Indiana, LLC – Franklin

Franklin, Indiana, United States, 46131

Contact    3177387400      

Principal Investigator: George Mitchell Cornett         

American Health Network of Indiana, LLC – Muncie

Muncie, Indiana, United States, 47304

Contact    7652132892      

Principal Investigator: Jonathan David Condit         

Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, United States, 50265

Contact    515-329-6800      

Principal Investigator: Anuj Bhargava         

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy, Michigan, United States, 48098

Contact    248-312-0025      

Principal Investigator: Neil J. Fraser         

Clinvest Research LLC

Springfield, Missouri, United States, 65807

Contact    4178837889      

Principal Investigator: David Gregory True         

University Of Nebraska Medical Center

Omaha, Nebraska, United States, 68198-4130

Contact    402-559-6276      

Principal Investigator: Cyrus Desouza         

Mid Hudson Medical Research

New Windsor, New York, United States, 12553

Principal Investigator: Sashi K. Makam         

Meridian Clinical Research, LLC

Vestal, New York, United States, 13850

Contact    607-794-5790      

Principal Investigator: Suchet R. Patel         

Alliance for Multispecialty Research, LLC

Norman, Oklahoma, United States, 73069

Contact    405-701-8999      

Principal Investigator: Lisa Connery         

Cascade Physicians

Tualatin, Oregon, United States, 97062

Contact    5035163837      

Principal Investigator: J. Thomas Forsythe         

Diabetes & Endocrinology Consultants of Pennsylvania, LLC

Feasterville-Trevose, Pennsylvania, United States, 19053

Contact    215-953-6804      

Principal Investigator: Arvind Cavale         

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

Pittsburgh, Pennsylvania, United States, 15236

Contact    412-650-6155      

Principal Investigator: Bryce A. Palchick         

WR-Clinsearch, LLC

Chattanooga, Tennessee, United States, 37397

Contact    423-698-4584      

Principal Investigator: Mark McKenzie         

Private Practice – Dr. Osvaldo A. Brusco

Corpus Christi, Texas, United States, 78414

Contact    3618850448      

Principal Investigator: Osvaldo Alejandro Brusco         

Velocity Clinical Research, Dallas

Dallas, Texas, United States, 75230

Contact    972-566-7799      

Principal Investigator: Julio Rosenstock         

Prime Revival Research Institute

Flower Mound, Texas, United States, 75028

Contact    214-432-1198      

Principal Investigator: WASIM A. HAQUE         

Endocrine Associates

Houston, Texas, United States, 77004

Contact    713-520-1110      

Principal Investigator: Gerardo Bueso         

Endocrine Ips, Pllc

Houston, Texas, United States, 77079

Contact    713-973-3415      

Principal Investigator: Amer S Al-Karadsheh         

North Hills Family Medicine/North Hills Medical Research

North Richland Hills, Texas, United States, 76180

Contact    817-595-3399      

Principal Investigator: John Gabriel         

Texas Valley Clinical Research

Weslaco, Texas, United States, 78596

Contact    9564318090      

Principal Investigator: Eduardo Dusty Luna         

Eastside Research Associates

Redmond, Washington, United States, 98052

Contact    425-869-6828      

Principal Investigator: Chad Crystal         

Centro de Investigaciones Metabólicas (CINME)

Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina, 1056

Contact    00541150319914      

Principal Investigator: Federico C. Perez Manghi         

Instituto de Investigaciones Clínicas Mar del Plata

Mar del Plata, Buenos Aires, Argentina, 7600

Contact    542234963224      

Principal Investigator: Virginia L. Sernia         

DIM Clínica Privada

Ramos Mejía, Buenos Aires, Argentina, B1704ETD

Contact    541146562828      

Principal Investigator: Alejandra Camino         

Go Centro Medico San Nicolás

San Nicolas, Buenos Aires, Argentina, 2900

Contact    5493364571637      

Principal Investigator: Paulina Virginia Lanchiotti         

Asociación de Beneficencia Hospital Sirio Libanés

Buenos Aires, Buenos Air, Argentina, C1419AHN

Contact    541145740870      

Principal Investigator: Gustavo Daniel Frechtel         

Stat Research S.A.

Capital Federal, Buenos Air, Argentina, 1023

Contact    54114816673      

Principal Investigator: Lucas Lisandro Gutnisky         

Centro Médico Viamonte

Buenos Aires, Ciudad Aut, Argentina, C1120AAC

Contact    541149635650      

Principal Investigator: Diego Aizenberg         

Glenny Corp

Buenos Aires, Ciudad Aut, Argentina, C1430CKE

Contact    01145445522      

Principal Investigator: Martin Horacio Koretzky         

CEMEDIAB

C.a.b.a., Ciudad Aut, Argentina, C1205AAO

Contact    54911440547      

Principal Investigator: Alejandro Mario Chertkoff         

Investigaciones Medicas Imoba Srl

Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina, C1179AAB

Contact    541149831589      

Principal Investigator: Silvia Ines Orio         

CIPREC

Caba, Ciudad Autónoma De Buenos Aire, Argentina, C1061AAS

Contact    5491128690843      

Principal Investigator: Fernando Pedro Guerlloy         

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aire, Argentina, C1425AGC

Contact    541148019001      

Principal Investigator: Maria Jimena Coronel         

Centro Medico Privado San Vicente Diabetes

Cordoba, Córdoba, Argentina, 5006

Contact    03514584601      

Principal Investigator: MARIA ANDREA STEINACHER         

Instituto Médico Río Cuarto

Río Cuarto, Córdoba, Argentina, 5800

Contact    0358154223269      

Principal Investigator: Rodrigo Carnero         

CIPADI – Centro Integral de Prevencion y Atencion en Diabetes

Godoy Cruz, Mendoza, Argentina, M5501ARP

Contact    542614200345      

Principal Investigator: Pedro Rosario Fabian Calella         

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

Rosario, Santa Fe, Argentina, 2000

Contact    543416928531      

Principal Investigator: Horacio Angel Sessa         

Clínica Mayo

San Miguel de Tucuman, Tucumán, Argentina, 4000

Contact    5493815437454      

Principal Investigator: Maria Eugenia Valdez         

Fundación Respirar

Buenos Aires, Argentina, C1426ABP

Contact    541170781548      

Principal Investigator: Maria Cristina De Salvo         

CENUDIAB

Ciudad Autónoma de Buenos Aire, Argentina, C1440AAD

Contact    1146820269      

Principal Investigator: Alejandra Isabel Oviedo         

Centro de Diagnóstico y Rehabilitación (CEDIR)

Santa Fe, Argentina, 3000

Contact    5493424087292      

Principal Investigator: Antonio Enrique Saleme         

Sanatorio Norte

Santiago del Estero, Argentina, 4200

Contact    0384154125573      

Principal Investigator: Franklin Hector Abalos         

RM Pharma Specialists

Mexico City, Distrito Federal, Mexico, 3100

Contact    525565501629      

Principal Investigator: Mariana Zolandi Crespo Hernández         

Instituto Jalisciense de Investigacion en Diabetes y Obesidad

Guadalajara, Jalisco, Mexico, 04460

Contact    523336153477      

Principal Investigator: Guillermo G. Gonzalez Galvez         

Diseno y Planeacion en Investigacion Medica

Guadalajara, Jalisco, Mexico, 44130

Contact    5233305493      

Principal Investigator: Cesar Gonzalo Calvo         

Instituto de Diabetes, Obesidad y Nutricion

Cuernavaca, Morelos, Mexico, 62250

Contact    7771022899      

Principal Investigator: Leobardo Sauque Reyna         

Hospital Universitario “Dr. Jose Eleuterio Gonzalez”

Monterrey, Nuevo León, Mexico, 64460

Contact    528183483220      

Principal Investigator: Jose Gerardo Gonzalez-Gonzalez         

Hospital Universitario “Dr. Jose Eleuterio Gonzalez”

Monterrey, Nuevo León, Mexico, 66460

Contact    528183482015      

Principal Investigator: Pedro Alberto Garcia         

Unidad Médica para la Salud Integral

San Nicolás de los Garza, Nuevo León, Mexico, 66465

Contact    52818348897      

Principal Investigator: Ramiro Guadalupe Banda Elizondo         

Medical Care and Research SA de CV

Merida, Yucatán, Mexico, 97070

Contact    9999203879      

Principal Investigator: Carlos Eduardo Medina         

Investigacion En Salud Y Metabolismo Sc

Chihuahua, Mexico, 31217

Contact    526144398618      

Principal Investigator: Luis Alejandro Nevarez         

Ponce Medical School Foundation Inc.

Ponce, Puerto Rico, 00716

Contact    17878402505      

Principal Investigator: Elizabeth A. Barranco-Santana         

Latin Clinical Trial Center

San Juan, Puerto Rico, 00909

Contact    7879859911      

Principal Investigator: Alex Gonzalez-Bossolo         

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes

Experimental: Control-IQ 2.0 Alternate Target
Participants will use t:slim X2 pump with Control-IQ technology 2.0 at an alternate target for two weeks.
Device: t:slim X2 insulin pump with Control-IQ technology 2.0
t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging

The goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast cancer. Participants will be treated with standard of care aromatase inhibitor therapy and will undergo serial phlebotomy, complete patient-reported questionnaires, and submit serial stool samples.
The main exploratory translational questions it aims to obtain preliminary data for are:

What are the effects of aromatase inhibitor therapy on biomarkers of aging?
What are the effects of aromatase inhibitor therapy on the microbiome? These data will be used for the development of future definitive studies.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 27, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

PRIMARY OBJECTIVE:
I. To compare persistence with the initially prescribed oral endocrine therapy (ET) through 72 weeks for young women being treated for hormone-receptor positive stage I-III breast cancer randomized to Active Symptom Monitoring (ASM) + patient education or patient education alone.
SECONDARY OBJECTIVES:
I. To compare patient-reported adherence with the initially prescribed oral ET over time as assessed with the Voils measure between the two arms.
II. To compare worst pain as assessed with the Brief Pain Inventory, in aromatase inhibitors-treated (AI-treated) participants over time between the two arms.
III. To compare hot flashes as assessed with the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) Endocrine Symptoms Scale in tamoxifen-treated participants over time between the two arms.
EXPLORATORY OBJECTIVES:
I. To describe key treatment-emergent symptoms as assessed with the Brief Pain Inventory, the Patient-Reported Outcomes Measurement Information System (PROMIS-29) Profile, the PROMIS Cognitive Function, and the FACT-ES Endocrine Symptoms Scale over time between the two arms.
II. To develop a composite risk prediction model (including demographics, socioeconomic variables, and clinical variables) to identify participants who are most likely to benefit from ASM.
III. To examine associations between baseline symptom bother as assessed with the GP5 item from the FACT-ES and persistence with oral ET.
IV. To examine the pattern by arm of treatment toxicity from the oral ET agents that are prescribed in this study over time during the first 24 weeks.
V. To compare biochemically determined adherence with the initially prescribed oral ET as assessed with centrally evaluated drug concentrations and metabolites between ASM + patient education and patient education alone over time.
VI. To examine associations overall and by arm between baseline estradiol concentrations evaluated centrally and development of treatment-emergent symptoms as assessed with the Brief Pain Inventory, the PROMIS-29 Profile, the PROMIS Cognitive Function, and the FACT-ES endocrine symptoms scale.
VII. To determine patterns of change overall and by arm in centrally evaluated estradiol concentrations during study participation in participants with chemotherapy-induced ovarian failure, those receiving gonadotrophin releasing hormone (GnRH) agonist therapy, and those who had undergone bilateral salpingo-oophorectomy.
VIII: To identify inherited genetic variants using genome-wide genotyping that contribute to development of endocrine therapy-emergent toxicity.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months.
ARM II: Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 27, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Nanopore Sequencing for Detecting Bacteria in Bile and Preventing Surgical Site Infections in Patients Undergoing Surgery for Benign or Malignant Pancreatic Tumors

PRIMARY OBJECTIVES:
I. Reduce the rate of bacterobilia driven surgical site infection (SSI) in patients undergoing pancreatic head resection by providing surgical team with nanopore sequencing (NS) data in the post-operative setting.
II. Reduce cost of care through reduction in SSI and improved antibiotic stewardship.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo the collection of bile samples during standard of care surgery. Samples undergo routine laboratory testing.
ARM II: Patients undergo the collection of bile samples during standard of care surgery. Samples undergo nanopore sequencing and routine laboratory testing.
After completion of study, patients’ medical records are reviewed for 30 days.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 27, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy

Experimental: Multi contact electrode implant and implanted electromyography recording electrodes

Fifteen subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.
During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode.

Device: Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode
See arm description
Other Name: Sensory Neuroprosthesis

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 27, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Immediate Postpartum Glucose Tolerance Testing

Gestational diabetes affects approximately 5-10% of pregnancies and its prevalence continues to increase as rates of obesity and metabolic disease increase in reproductive age women. Women diagnosed with gestational diabetes carry an increased risk of developing type 2 diabetes later in life, even if their glucose tolerance initially normalizes following delivery.
The gold standard assessment of glucose tolerance postpartum is a two hour glucose tolerance test (GTT) that is completed between six and twelve weeks’ postpartum. Unfortunately, the compliance rate with this test is low, ranging from 30 – 50% by most reports. As a result, a large number of women with glucose intolerance are missed due to noncompliance with postpartum testing, thereby forfeiting the opportunity for diagnosis, treatment and prevention of longterm health consequences. The postpartum hospital stay provides a unique opportunity to increase compliance with glucose tolerance testing due to an increased rate of patient capture. However, it is unknown if administration of a glucose tolerance test in the immediate postpartum period would adequately identify women with persistent glucose intolerance.
The current study aims to provide data towards the accuracy of an immediate postpartum GTT in a population of women with gestational diabetes and provide follow-up data on women with abnormal testing.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 27, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine